animals, is a complex behavior orchestrated by a multitude of signaling molecules released from central and peripheral neurons and/or cells. Signaling molecules including ghrelin, orexins, adiponectin, agouti-related peptide, and cocaine-amphetamine regulated transcript peptide that prompt or suppress feedings, have been identified in the last few years (1-5). Nesfatin-1, an amino-terminal fragment derived from NEFA/nucleobindin 2 (NUCB2), is a recently identified satiety molecule (6). Immunohistochemical studies show that in the rat nesfatin-1-immunoreactivity (irNEF) is expressed in several discrete nuclei of the hypothalamus including the paraventricular (PVN) and supraoptic (SO) nucleus, the arcuate nucleus (Arc), the lateral hypothalamic area, and the zona incerta (6). In addition to the hypothalamus, irNEF is detectable in neurons of the nucleus of solitary tract (NTS) (6). This study had as its first aim the characterization of the phenotype of irNEF neurons in the hypothalamus and NTS as well as the newly identified areas by double-immunolabeling the sections with nesfatin-1 antiserum and antiserum to putative transmitters/enzymes known to express in respective areas.
animals, is a complex behavior orchestrated by a multitude of signaling molecules released from central and peripheral neurons and/or cells. Signaling molecules including ghrelin, orexins, adiponectin, agouti-related peptide, and cocaine-amphetamine regulated transcript peptide that prompt or suppress feedings, have been identified in the last few years (1) (2) (3) (4) (5) . Nesfatin-1, an amino-terminal fragment derived from NEFA/nucleobindin 2 (NUCB2), is a recently identified satiety molecule (6) . Immunohistochemical studies show that in the rat nesfatin-1-immunoreactivity (irNEF) is expressed in several discrete nuclei of the hypothalamus including the paraventricular (PVN) and supraoptic (SO) nucleus, the arcuate nucleus (Arc), the lateral hypothalamic area, and the zona incerta (6) . In addition to the hypothalamus, irNEF is detectable in neurons of the nucleus of solitary tract (NTS) (6) . This study had as its first aim the characterization of the phenotype of irNEF neurons in the hypothalamus and NTS as well as the newly identified areas by double-immunolabeling the sections with nesfatin-1 antiserum and antiserum to putative transmitters/enzymes known to express in respective areas.
Nesfatin-1 injected intracerebroventricularly to the rats reduced body weight in a dose-dependent manner, whereas injection of the antisense morpholino oligonucleotide against the gene encoding nucleobindin 2 increased body weight (6) . Central administration of ␣-MSH elevated NUCB2 gene expression in the PVN, and prior administration of the melanocortin 3/4 receptor antagonist SHU9119 eliminated the nesfatin-1-induced satiety in rats, implying that a component of nesfatin-1 signaling pathway involves melanocortin (6) . The receptor pharmacology and signaling mechanism directly associated with the action of nesfatin-1, however, has not been explored. With few exceptions, peptides including satiety and antisatiety molecules signal through G proteincoupled receptors. It is therefore hypothesized that nesfatin-1 interacts with a G protein-coupled receptor. The second aim was to explore the pharmacological property of the putative receptor or binding site, using Ca 2ϩ flux as an indicator.
Immunohistochemistry
Animals anesthetized with urethane (1.2 g/kg, ip) were intracardially perfused with 0.1 m PBS followed by 4% paraformaldehyde/0.2% picric acid in PBS. Brains were removed, postfixed for 2 h, and stored in 30% sucrose/PBS solution overnight.
In single staining, tissues were processed for irNEF by the avidinbiotin complex procedure (7) . The brain was embedded in agar and coronal sections of 50 m thickness were prepared with the use of a Vibratome. Tissues were first treated with 3% H 2 O 2 to quench endogenous peroxidase, washed several times, blocked with 10% normal goat serum, and incubated in nesfatin-1 antiserum (1:1000 dilution), which was a rabbit polyclonal raised against the rat nesfatin-1 N terminus (1-82) (Phoenix Pharmaceuticals, Inc., Burlingame, CA). Nesfatin-1 antiserum cross-reacts 100% with rat nesfatin-1 (1-82) and does not crossreact with the following peptides: nesfatin-1 (1-45, human), nesfatin-1 (47-82, human), agouti-related peptide (83-132, human), ␣-MSH, orexin A (human, rat, mouse), neuropeptide Y (rat), ghrelin (rat, mouse), and obestatin (rat, mouse). After thorough rinsing, sections were incubated in biotinylated antirabbit IgG (1:200 dilution; Vector Laboratories, Burlingame, CA) for 2 h and rinsed with PBS and incubated in avidin-biotin complex solution for 1.5 h (1:100 dilution; Vector Laboratories). After several washes in Tris-buffered saline, sections were developed in 0.05% diaminobenzidine/0.001% H 2 O 2 solution and washed for at least 2 h with Tris-buffered saline. Sections were mounted on slides with 0.25% gel alcohol, air dried, dehydrated with absolute alcohol followed by xylene, and coverslipped with Permount.
For control experiments, sections were processed with nesfatin-antiserum preabsorbed with the rat nesfatin-1 peptide (1-82) (10 g/ml) overnight or by substituting nesfatin-1 antiserum with normal rabbit serum.
In the case of double-labeling experiments, hypothalamic and medullary sections were first blocked with normal goat serum (1:10 in PBS, 0.5% BSA, 0.4% Triton X-100) and then incubated with nesfatin-1 antiserum (1:500 dilution). After several washes with PBS, sections were incubated with biotinylated antirabbit IgG (1:50, Vector Laboratories), washed with PBS, and incubated with fluorescein avidin D. After rinsing with PBS, hypothalamic sections were blocked with normal donkey serum (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) and incubated with oxytocin (OT) antibody (1:1000 dilution, a monoclonal from Chemicon, Temecula, CA), vasopressin (VP) antiserum (1: 1500 dilution, a guinea pig polyclonal from Chemicon), tyrosine hydroxylase (TH) antibody (1:750, a mouse monoclonal from Chemicon), neuropeptide Y (NPY) antiserum (1:750, a sheep polyclonal from Chemicon), cocaine-amphetamine-regulated transcript antiserum (CART; 1:500; Phoenix Pharmaceuticals), melanin-concentrating hormone antiserum (MCH; 1:300; Phoenix Pharmaceuticals), and proopiomelanocortin (POMC; 1:400; Phoenix Pharmaceuticals) antiserum. Medullary sections were incubated with choline acetyltransferase (ChAT) antiserum (1:200; a guinea pig polyclonal from Bachem BioSciences Inc., King of Prussia, PA), 5-HT antiserum (1:300, a goat polyclonal from Chemicon), TH antiserum, or POMC antiserum for 48 h in a cold room. Tissues were then incubated in appropriate IgG Texas Red antibodies, washed with PBS, and mounted in Citifluor and coverslipped. Sections were examined under a confocal scanning laser microscope (TCS SL; Leica Microsystems Inc., Exton, PA) with excitation/emission wavelengths set to 488/520 nm for fluorescein isothiocyanate and 543/620 nm for Texas Red in the sequential mode.
Neuronal cell culture
Cells were isolated from the hypothalamus of postnatal 1-to 3-d-old rats by enzymatic digestion with 0.5 mg papain per 100 mg tissue (8) . Cells were plated at a density of 10 3 cells/mm 2 in a Neurobasal-A medium, supplemented with 10% fetal calf serum, 2 mm glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin (Invitrogen, Carlsbad, CA), and maintained at 37 C in a humidified atmosphere with 5% CO 2 . Glial cell growth was inhibited by the mitotic inhibitor cytosine ␤-arabino furanoside (1 m) (Sigma, St. Louis, MO). Neurons were cultured for 5 d. Cells were transferred to a medium without fetal serum 12 h before Ca 2ϩ measurements.
Cytosolic Ca 2ϩ concentrations
Cytosolic Ca 2ϩ measurements were performed as described previously (8, 9) . Cells were incubated with 5 m fura-2AM (Molecular Probes, Eugene, OR) in Hanks' balanced salt solution (HBSS) at room temperature for 45 min in the dark, washed three times with dye-free buffer, and then incubated for another 45 min to allow for complete deesterification of the dye. Coverslips were subsequently mounted in a custom-designed bath on the stage of an Eclipse TE 2000-U (Nikon, Tokyo, Japan) inverted microscope equipped with a CCD camera (Roper Scientific, Tucson, AZ). Cells were routinely superfused with HBSS at a flow rate of 1 ml/min. Fura-2 fluorescence (emission ϭ 510 nm), after alternate excitation at 340 and 380 nm, was acquired at a frequency of 0.33 Hz. Images were acquired and analyzed using Metafluor software. For Ca 2ϩ -free experiments, HBSS without Ca 2ϩ and supplemented with 2.5 mm EGTA was used.
Statistical analysis
In calcium measurement experiments, statistical significance between groups was tested using one-way ANOVA followed by Bonferroni test, P Ͻ 0.05 being considered significant. 
Results

Immunohistochemistry
Single labeling results were obtained from four male and four female adult Sprague Dawley rats. In addition, brain tissues from two male rats were processed for double labeling. The pattern of distribution of irNEF cells was similar in male and female rats. In addition to the hypothalamus and NTS, irNEF neurons were noted in several areas not previously reported (6) . A more extensive description of the distribution of irNEF neurons is therefore presented below.
Hypothalamus
Positively labeled cells were distributed to the PVN and SO; few cells were scattered in the periventricular hypothalamic nucleus and the retrochiasmatic nucleus (Fig. 1, A-C) . Within the PVN, irNEF cells were concentrated in the lateral magnocellular part and ventral part (PaV), with fewer cells in the medial parvicellular part (Fig. 1, A and B) . At the level of median eminence, numerous irNEF cells were noted in the lateral hypothalamic area (LH), zona incerta, perifornical nucleus, dorsal hypothalamic area (DA), and Arc (Fig. 1 , D-F). At a more caudal level, irNEF neurons were distributed to the LH, subincertal nucleus, DA, and Arc as well as the dorsomedial nucleus, dorsal, ventromedial hypothalamic nucleus, and supraoptic retrochiasmatic nucleus (SOR) (Fig.  2, A and B) . Overall, the distribution of irNEF neurons observed in the hypothalamus was similar to that reported earlier (6) .
Control studies
Hypothalamic or medullary sections processed with nesfastin-1 antiserum preabsorbed with the peptide (10 g/ml) showed no labeled cells. A hypothalamic section labeled with nesfastin-1 antiserum showed numerous irNEF neurons in the LH, perifornical nucleus, and Arc (Fig. 2C) , whereas positively labeled cells were not detected in an adjacent hypothalamic section processed with nesfatin-1 antiserum preabsorbed with the peptide overnight (Fig. 2D) . Similarly, substitution of nesfatin-1 antiserum with normal rabbit serum resulted in no immunoreactivity in any of the sections examined.
Pons and medulla oblongata
Similar to an earlier report (6) , irNEF cells were detected in the nucleus of solitary tract (Fig. 3, A and B) . Moderately labeled cells could also be detected in the dorsal motor nucleus of vagus (10) (Fig. 3, A and B) . In addition, the EdingerWestphal (EW) nucleus contained irNEF neurons (Fig. 3C) . Cells in the caudal raphe nuclei including the nucleus raphe obscurus (ROb) and raphe pallidus (RPa) expressed irNEF (Fig. 3D) .
Double-labeling studies
Neurons in the PVN and SO contain VP or OT (11) . Double labeling the hypothalamic sections with nesfatin-1 antiserum and VP antiserum or OT antiserum revealed that some of the irNEF neurons were VP positive and others were OT positive (Fig. 4, A1-A3 , and B1-B3). Some of the neurons in the Arc contain the catecholaminergic neuron marker tyrosine hydroxylase (TH) (12, 13) . Double labeling the hypothalamic sections with nesfatin-1 antiserum and TH antiserum showed that in the Arc some of the irNEF cells exhibit TH immunoreactivity (Fig. 4, C1-C3 ). Whereas irNEF was not detectable in NPY-positive neurons, NPY-positive fibers were in close proximity to irNEF neurons in the Arc (Fig. 4 , D1-D3) and PVN. Some irNEF cells from the Arc were also CART positive (Fig. 4, E1-E3 ) or POMC positive (not shown). In the lateral hypothalamic area, irNEF was found in neurons exhibiting CART immunoreactivity (Fig. 4, F1-F3 ) or MCH immunoreactivity (Fig. 4, G1-G3 ), whereas NPY-positive fibers were identified in the vicinity of irNEF neurons (Fig. 4,  H1-H3) .
With respect to the brainstem, double-labeling experiments showed that the majority of irNEF neurons were TH positive (Fig. 4, I1-I3 shown). Lastly, irNEF cells in the caudal raphe nuclei were 5-HT immunoreactive (Fig. 4, J1-J3 ).
Intracellular Ca 2ϩ concentrations
The neuronal activity of nesfatin (Fig. 5C) ; the average increase of [Ca 2ϩ ] i was 24 Ϯ 1.6 nm (n ϭ 26) above the basal level in cells pretreated with KT 5720 (Fig. 6) .
Discussion
Similar to the pattern of distribution first described by Oh-1 et al. (6) using immunohistochemistry and in situ hybridization, our result shows that irNEF cells are present in the hypothalamus and NTS. In addition, our result reveal several groups of irNEF neurons in the brainstem that were not reported earlier, namely the EW nucleus, DMNV, ROb, and RPa nuclei. Because the number of labeled cells in these nuclei is relatively small, they may have been overlooked in the early study (6) . Doublelabeling studies reveal a heterogeneous population of neurons expressing irNEF that are area specific. For example, irNEF is expressed in VP or OT cells of the PVN and SO and in THpositive as well as CART-positive cells of the Arc. In the lateral hypothalamus, irNEF are colocalized with CART and MCH. In the brainstem, irNEF is expressed in ChAT-positive, thus cholinergic, neurons of the EW nucleus and DMNV; catecholaminergic neurons of the NTS; and serotoninergic cells of the caudal raphe nuclei.
Several lines of evidence suggest that nesfatin-1 may function as an anorexigenic peptide (6). Nesfatin-1 gene and protein are found in the hypothalamic nuclei known to be involved in feeding behaviors, food intake, body weight, and glucose homeostasis (15) . The Arc is the major site in which leptin activates POMC and CART neurons but inhibits agouti-related peptide (AGRP) and NPY neurons (10, 16, 17) . POMC/CART and AGRP/NPY neurons are distinct populations in the Arc (18) . Double-labeling studies demonstrate that irNEF is expressed in CART-positive and POMC-positive but not NPY-positive neurons; instead, NPY-immunoreactive fibers appear to be in close proximity to irNEF neurons in the Arc, PVN, and LH. Because almost all CART neurons are found to contain POMC and vice versa (19) , the colocalization of nesfatin-1 with both CART and POMC is not unexpected. Nesfatin-1 by intracerebroventricular injection was found not to affect the expression of genes encoding POMC, AGRP, and NPY in the Arc, suggesting a leptinindependent signaling (6). In the Arc, some of the irNEF are also TH positive; the latter belong to dopaminergic neurons of the tuberoinfundibular system, which regulates the secretion of prolactin (20, 21) .
In the case of PVN and SO, irNEF neurons are found to overlap with VP or OT cells. CRH is also known to be localized in a population of VP and OT neurons (22) . Nesfatin-1 injected intraventricularly did not significantly modify the expression of the gene encoding CRH (6) , suggesting that CRH neurons may not be the primary target of nesfatin-1 in the hypothalamus.
The largest number of irNEF neurons is found in the LH, which contain a heterogeneous group of neurons expressing diverse transmitter phenotypes. Our result shows that in the lateral hypothalamic area some of the irNEF neurons exhibit CART or MCH immunoreactivity and are surrounded by NPYpositive fibers. Neurons in the LH are known to be closely associated with food intake, body weight, and other metabolic processes (23) . The role of nesfatin-1 in this integrative circuitry subserving the ingestive behavior remains to be explored. The colocalization of nesfatin-1 with peptides having both stimulatory (MCH) and inhibitory (CART) effect on feeding is not without precedent because CART is also identified in POMCand MCH-containing neurons (19) .
In addition to the hypothalamus, irNEF neurons are noted in the NTS, as reported by Oh-I et al. (6) . Double-labeling experiments demonstrate that irNEF neurons in the NTS contain TH, thus are catecholaminergic. In addition, irNEF neurons in the NTS expressed varying levels of POMC immunoreactivity. A large percentage of catecholaminergic neurons in the NTS projects to the PVN (24) . As a corollary, irNEF neurons in the NTS send their axons to the PVN, in which the peptide may modulate the activity of PVN.
Three additional groups of irNEF neurons are identified in the brainstem, namely the EW nucleus, DMNV, and caudal raphe nuclei. Double-labeling studies show that irNEF neurons are ChAT positive in the EW nucleus and DMNV and 5-HTpositive in the caudal raphe nuclei. A large majority of neurons in the DMNV innervate the gastrointestinal tract (25) . Viewed in this context, nesfatin-1 released from the vagus nerve may modify the activity of gastrointestinal tract, which is consistent with the notion that nesfatin-1 regulates ingestive behaviors. On the other hand, the functional significance of nesfatin-1 in neurons of the EW nucleus is not clear. The EW nucleus contains preganglionic parasympathetic neurons whose axons end in the ciliary ganglion, which in turn send their axons to the sphincter pupillae of the iris and the ciliary muscles of the eye. Other peptides known to be present in the EW nucleus, such as urocortin and CART, are involved in the regulation of feeding and response to stress (26, 27) .
With respect to the caudal raphe nuclei, irNEF is present in some of the serotoninergic neurons of the RPa and ROb. In addition to projecting to the brainstem and spinal cord and participating in the regulation of motor and somatosensory functions (28, 29) , some of the serotoninergic neurons are thought to be sympathetic premotor neurons with brown fat pads as their target sites (30, 31) . Thus, nesfatin-1 via this sympathetic bulbospinal pathway may play a role in thermogenesis and related energy homeostasis.
Using Ca 2ϩ flux as an index, our result suggests that nesfatin-1 interacts with a receptor with pharmacological characteristics of a G protein-coupled receptor in the cultured rat hypothalamic neurons. Nesfatin-1 induced an elevation of [Ca 2ϩ ] i characterized by a relatively fast rise followed by a plateau. The response is abolished by pertussis toxin, indicating the participation of a G i/o protein coupled receptor. Nesfatin-1-induced calcium increases were abolished in a Ca 2ϩ -free medium, indicating that the peptide increases Ca 2ϩ influx from the extracellular space. Results obtained with inhibitors specific for subtypes of Ca 2ϩ channels indicate that the calcium channel activated by nesfatin-1 exhibits pharmacological characteristics of L and P/Q channels.
The specific protein kinase A inhibitor KT 5720 (32), which is plasma membrane permeable, has been previously demonstrated to be effective in neurons at the concentrations used in our study (33) (34) (35) . Nesfatin-1-induced elevation of [Ca 2ϩ ] i was significantly reduced by KT 5720, suggesting an involvement of protein kinase A in nesfatin-1-induced Ca 2ϩ responses in hypothalamic neurons. This is unexpected because activation of G i is generally associated with a decrease of cAMP levels (36) . One possible explanation is that one agonist can activate different pathways by switching receptor coupling between different G proteins (37) . For example, nesfatin-1 may initially activate G i and later switch to G s stimulation. A sequential activation has been shown for G s /G i but not G i /G s (38) . Consequently, this model may not be applicable to our observation. A recent observation by Dunn et al. (39) , who measured concomitantly intracellular Ca 2ϩ /cAMP levels and protein kinase A activity reveals that, in neonatal rat retinal explants, Ca 2ϩ entry through plasmalemma but not Ca 2ϩ release from internal sources activates cAMP production in seconds. Moreover, it has been
FIG. 6. Comparison of changes in Ca
2ϩ induced by nesfatin-1 in different experimental conditions. Nesfatin-1 (100 nM) induced an increase of [Ca 2ϩ ] i by 164 ϩ 3.6 nM (n ϭ 11, first column), which was reduced by pretreatment with verapamil alone (1 M, 30 min; n ϭ 8) or in combination with -conotoxin GVIA (0.1 M, 1 h; n ϭ 9), and by pretreatment with KT 5720 (1 M, 30 min; n ϭ 26). The Ca 2ϩ response to nesfatin-1 was abolished by pretreatment with pertussis toxin (100 ng/ml, 1 h; n ϭ 47), verapamil, and -conotoxin MVIIC (0.1 M, 1 h; n ϭ 31) or by perfusion with Ca 2ϩ -free saline (n ϭ 38). *, Statistically significant difference (P Ͻ 0.05) as compared with nesfatin-1; **, statistically significant difference as compared with nesfatin-1 and verapamil, nesfatin-1 and verapamil ϩ -conotoxin GVIA, nesfatin-1, and KT 5720.
shown that activation of G i induces a functional compartmentalization of protein kinase A signaling (40) . Our interpretation is that nesfatin-1 activates spatiotemporary restricted Ca 2ϩ and protein kinase A signaling, leading to a highly specific role in intracellular signaling cascade.
In summary, our result shows that in the rat nesfatin-1 is expressed in discrete populations of hypothalamic and brainstem neurons and that the peptide stimulates calcium influx in cultured hypothalamic neurons by interacting with a yet to be identified G protein-coupled receptor.
